Long-term follow-up of autologous peripheral blood stem cell transplantation in the treatment of a patient with acute panmyelosis with myelofibrosis.
Ngirabacu
M C
MC
Dept d'Hématologie de l'Institut J Bordet (Université libre de Bruxelles), Brussels, Belgium.
Ravoet
C
C
Dargent
J L
JL
Meuleman
N
N
Ahmad
I
I
Ysebrant
L
L
Bennani
J
J
André
M
M
Bron
D
D
D000208:Acute Disease; D000753:Anemia, Refractory / Q000188:drug therapy / Q000209:etiology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D004921:Erythropoietin / Q000627:therapeutic use; D005047:Etoposide / Q000008:administration & dosage; D005500:Follow-Up Studies; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D036102:Peripheral Blood Stem Cell Transplantation; D011183:Postoperative Complications / Q000188:drug therapy / Q000209:etiology; D055728:Primary Myelofibrosis / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D011994:Recombinant Proteins; D019172:Transplantation Conditioning / Q000009:adverse effects; D014182:Transplantation, Autologous; D014916:Whole-Body Irradiation / Q000009:adverse effects
D011994:Recombinant Proteins; D003561:Cytarabine; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D008942:Mitoxantrone; D008727:Methotrexate